Researchers Identify Epstein-Barr Virus' Weak Points

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

Related Keywords

Jeffreyi Cohen , ,Technology Network ,National Institute Of Allergy ,National Institutes Of Health ,National Institute ,Infectious Diseases ,National Institutes ,